In the first wave of the pandemic, SAFER was set up to answer questions around the proportion of frontline NHS staff in acute care who contracted COVID-19, the immune response to SARS-CoV-2 infection, the frequency of asymptomatic infection and persistence (or not) of antibodies.
As the pandemic progresses, we aim to answer key questions with SAFER-PLUS around vaccine effectiveness, the protection from infection which is asymptomatic, the risk of re-infection after the initial infection and the infectivity of the virus and how this differs post vaccination. In addition, we will explore how the virus evolves over time and what the impact of virus variants is. We will monitor immune responses over time and our data will also contribute to National data informing National policy.
Virology, Immune response and Epidemiology Team
Professor Andrew HaywardProfessor of Infectious Disease Epidemiology
Dr Eleni NastouliChief Investigator of SAFER
Head of Virology and Director of Advanced Pathogen Diagnostics Unit, UCLH
Associate Professor, UCL and the Francis Crick Institute
Dr Catherine HoulihanUCLH Principle Investigator for SAFER, Consultant in Clinical Virology at UCLH, Honorary Assistant Professor at UCL in the Division of Infection and Immunity
Professor George KassiotisSenior Group Leader and head of the laboratory of Retroviral Immunology at the Francis Crick Institute, London, UK
Dr Laura McCoyMRC Career Development Fellow in the Division of Infection and Immunity at UCL
Professor Richard GilsonProfessor of Sexual Health and HIV Medicine at UCL and Honorary Consultant at the Mortimer Market Centre, Central and North West London NHS Foundation Trust